Type 1 diabetes has a very high treatment burden in terms of direct costs, inconvenience and lost productivity for patients and their carers. Further, all the glucose checking, hormone replacement and consults don’t abolish the vascular complications associated with poor glycaemic control. Only in the last few years has it been possible to pharmacologically alter the course of type 1 diabetes and other auto-immune diseases without generating intolerable side effects.
Teplizumab is an antibody to CD3 which was presented to the world in 2019 as delaying the onset of type 1 diabetes in high-risk individuals thanks to its protective effect on pancreatic β-cells. It has not yet been registered by the Therapeutic Goods Administration but another drug immunomodulatory drug called baricitinib has. Baricitinib is an inhibitor of Janus Kinases indicated for the for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis and even COVID-19.
In December of last year the results of a Phase 2 trial in patients with new-onset type 1 diabetes were published in the New England Journal of Medicine. After almost a year of taking the oral therapy, patients were found to have better glycaemic control and evoked C-peptide levels than those taking placebo, indicating a preserved ability to secrete insulin. In today’s, Pomegranate’s in-house endocrinologist interviews two of the study authors.
Key Reference
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes [NEJM. 2023. 7;389(23)]
Guests
Prof Jenny Couper FRACP FAHMS (Women's and Children's Hospital, University of Adelaide)
Dr Michelle So FRACP (Royal Melbourne Hospital, Northern Hospital)
Guest Host
Dr Rahul Barmanray FRACP (Royal Melbourne Hospital)
Production
Produced by Mic Cavazzini DPhil. Music licenced from Epidemic Sound includes ‘Things to Sort out’ and ‘Quiet Waters’ by Walt Adams and ‘The Appalachian Trail’ by Hunter Quinn. Music courtesy of FreeMusic Archive includes ‘I am a Man Who Will Fight For Your Honor’ by Chris Zabriskie. Image produced and copyrighted by RACP.
Editorial feedback kindly provided by RACP physicians Amy Hughes, Stephen Bacchi, Fionnuala Fagan and Aidan Tan.
Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health’ in Apple Podcasts, Spotify,Castbox or any podcasting app.
[Case Report] 68yo with cardiometabolic risk factors and transient monocular vision loss
Ep106: The whiskey fix and the apple of Granada
Ep105: When parents and paediatrics clash
[IMJ On-Air] Is the jury still out on omega-3 supplementation?
[IMJ On-Air] HepatoCare: a model for palliative and supportive care in advanced cirrhosis
Ep102: Staying on script with semaglutide
Ep101: Setting the standard for workforce wellbeing
Ep100: Conversations with ChatGPT
Ep99: When AI goes wrong
[IMJ On-Air] A tiger in the mallee: Victoria’s JEV cluster
Ep97: The governance of AI
Ep96: The ergonomics of AI
Ep95: Machine Learning 101
Ep94: Facing up to racial bias
Ep93: The rise and fall of mpox
Ep92: Data-driven practice improvement
[IMJ On-Air] Hyperglycaemia and COVID-19
[IMJ On-Air] High readmission rates in cirrhotic patients
Ep89: What we know about long COVID
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive